Delivery Order SPE2DB25D3504-SPE2DB25FVUKK
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 50 mg capsules (quantity 100s) on April 22, 2025, with a ceiling value of $1,642.71 and an ultimate completion date of April 23, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100-count units) on August 25, 2025, with a ceiling value of $1,781.07 and an ultimate completion date of August 26, 2025. This contract was awarded competitively with no set-aside designation and utilizes firm fixed-price pricing. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $2,174.23 to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) on June 2, 2025, with an ultimate completion date of June 3, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Vyvanse 10 mg capsules (100-count units) with a ceiling value of $5,729.59. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set to conclude on June 20, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $23,405.42 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This non-set-aside, firm fixed-price delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $1,042.70. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $1,120.83. This firm fixed-price delivery order, with an ultimate completion date of August 5, 2025, represents a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is issued under the company's larger...
- SPE2DB25D3504Indefinite Delivery Contract
- SPE2DB25D3504-SPE2DB25FVUKKDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) at a ceiling value of $1,178.44. This competitively awarded, firm fixed-price delivery order is scheduled for completion by April 25, 2025, with performance originating from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle active through December 2026. AmerisourceBergen Drug Corp is one of the nation's leading pharmaceutical distributors and serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government healthcare entities. The company's extensive portfolio of federal contracts demonstrates its capability to supply a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Vyvanse—an FDA-approved amphetamine used to treat attention-deficit hyperactivity disorder and binge eating disorder—reflects the company's role in ensuring pharmaceutical availability within the military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 4/24/25 |